GeneDx (NASDAQ:WGS) Director Casdin Capital, Llc Buys 50,000 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc purchased 50,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were purchased at an average cost of $52.86 per share, for a total transaction of $2,643,000.00. Following the completion of the purchase, the director directly owned 3,707,164 shares of the company’s stock, valued at approximately $195,960,689.04. This represents a 1.37% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Casdin Capital, Llc also recently made the following trade(s):

• On Thursday, June 4th, Casdin Capital, Llc purchased 150,000 shares of GeneDx stock. The shares were purchased at an average price of $56.44 per share, for a total transaction of $8,466,000.00.
• On Wednesday, May 20th, Casdin Capital, Llc purchased 140,000 shares of GeneDx stock. The shares were purchased at an average price of $43.81 per share, for a total transaction of $6,133,400.00.
• On Tuesday, May 19th, Casdin Capital, Llc purchased 185,000 shares of GeneDx stock. The shares were purchased at an average price of $42.60 per share, for a total transaction of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc purchased 175,000 shares of GeneDx stock. The shares were purchased at an average price of $42.55 per share, for a total transaction of $7,446,250.00.

GeneDx Trading Down 0.8%

Shares of NASDAQ:WGS traded down $0.41 during midday trading on Monday, hitting $51.80. 790,359 shares of the stock were exchanged, compared to its average volume of 1,036,153. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -19.33 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The business’s 50-day moving average price is $55.44 and its 200 day moving average price is $92.65. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter last year, the firm posted ($0.23) earnings per share. Analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Weiss Ratings downgraded shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Wall Street Zen cut shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research dropped their target price on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Piper Sandler reiterated an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Finally, Guggenheim lowered their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Institutional Trading of GeneDx

Large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp grew its position in shares of GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $27,000. Fifth Third Bancorp acquired a new stake in shares of GeneDx during the 1st quarter worth approximately $31,000. Quarry LP grew its position in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the period. Finally, Ramirez Asset Management Inc. acquired a new stake in shares of GeneDx during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
• Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
• Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
• Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.